Passkey Therapeutics

Passkey Therapeutics is pioneering a new class of drugs, known as Synergistic Multifunctional Therapies (SMThs), which aim to address complex diseases by targeting rare combinations of proteins with synergistic effects. The company focuses on discovering novel drugs for complex multifactorial diseases such as metabolic disorders and cancer, leveraging computational and genomic approaches to accelerate drug discovery, enabling the development of more effective treatments with potentially fewer side effects.